The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer.
 
Neal Shiv Chawla
No Relationships to Disclose
 
Nishita Tripathi
No Relationships to Disclose
 
Nicolas Sayegh
No Relationships to Disclose
 
Ameish Govindarajan
No Relationships to Disclose
 
Nazli Dizman
Consulting or Advisory Role - Vivreon Biosciences
 
Zeynep Busra Zengin
No Relationships to Disclose
 
Luis A Meza
No Relationships to Disclose
 
Ramya Muddasani
Stock and Other Ownership Interests - Abbvie; Abbvie; Actinium Pharmaceuticals; Actinium Pharmaceuticals (I); Advaxis (I); Agenus; Agenus (I); Aprea Therapeutics; Aprea Therapeutics (I); Athenex (I); AVEO (I); Cellectar; Cellectar (I); crispr therapeutics (I); Curis (I); DelMar Pharmaceuticals; DelMar Pharmaceuticals (I); DelMar Pharmaceuticals (I); Epizyme; Epizyme (I); Forty Seven; Forty Seven (I); Gritstone Bio (I); Heat Biologics (I); Immunomedics; Immunomedics (I); Mereo BioPharma (I); NantHealth (I); NantKwest,; NantKwest, (I); Novavax (I); Onconova Therapeutics; Onconova Therapeutics (I); Pfizer (I); Portola Pharmaceuticals (I); Vaxart
 
Alex Chehrazi-Raffle
No Relationships to Disclose
 
Sabrina Salgia
No Relationships to Disclose
 
Jasnoor Malhotra
No Relationships to Disclose
 
Joann Hsu
No Relationships to Disclose
 
Errol James Philip
No Relationships to Disclose
 
Cristiane Decat Bergerot
No Relationships to Disclose
 
Yung Lyou
Consulting or Advisory Role - Pfizer/EMD Serono; Seattle Genetics/Astellas
Speakers' Bureau - Janssen Oncology
 
Umang Swami
Consulting or Advisory Role - Seagen
Research Funding - Janssen (Inst); Seattle Genetics/Astellas (Inst)
 
Sumati Gupta
Stock and Other Ownership Interests - Salarius Pharmaceuticals (I)
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/Lilly (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); Immunocore (Inst); Incyte (Inst); LSK BioPharma (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); QED Therapeutics (Inst); Rexahn Pharmaceuticals (Inst); Seagen (Inst); Viralytics (Inst)
Travel, Accommodations, Expenses - QED Therapeutics
 
Benjamin L. Maughan
Consulting or Advisory Role - Astellas Medivation; AVEO; Bavarian Nordic; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Janssen Oncology; Merck; Peloton Therapeutics; Pfizer; Tempus
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
 
Sumanta K. Pal
Consulting or Advisory Role - F. Hoffmann LaRoche; F. Hoffmann LaRoche; Roche
Research Funding - Eisai (Inst); Exelixis (Inst); Genentech (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Genentech; Seagen